These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 36388140)
1. Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments. Richardson B; MacPherson A; Bambico F Brain Behav Immun Health; 2022 Dec; 26():100554. PubMed ID: 36388140 [TBL] [Abstract][Full Text] [Related]
2. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Bakunina N; Pariante CM; Zunszain PA Immunology; 2015 Mar; 144(3):365-373. PubMed ID: 25580634 [TBL] [Abstract][Full Text] [Related]
3. Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency. Nikkheslat N Brain Behav Immun Health; 2021 Dec; 18():100383. PubMed ID: 34849492 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder. Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917 [TBL] [Abstract][Full Text] [Related]
5. Physical Exercise and Neuroinflammation in Major Depressive Disorder. Ignácio ZM; da Silva RS; Plissari ME; Quevedo J; Réus GZ Mol Neurobiol; 2019 Dec; 56(12):8323-8335. PubMed ID: 31228000 [TBL] [Abstract][Full Text] [Related]
6. Translational evidence for the Inflammatory Response System (IRS)/Compensatory Immune Response System (CIRS) and neuroprogression theory of major depression. Debnath M; Berk M; Maes M Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110343. PubMed ID: 33961966 [TBL] [Abstract][Full Text] [Related]
7. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review. Sukhram SD; Yilmaz G; Gu J Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713 [TBL] [Abstract][Full Text] [Related]
9. From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder. Liu B; Liu J; Wang M; Zhang Y; Li L Front Cell Neurosci; 2017; 11():305. PubMed ID: 29033793 [TBL] [Abstract][Full Text] [Related]
10. Association between peripheral inflammation and free-water imaging in Major Depressive Disorder before and after ketamine treatment - A pilot study. Langhein M; Seitz-Holland J; Lyall AE; Pasternak O; Chunga N; Cetin-Karayumak S; Kubicki A; Mulert C; Espinoza RT; Narr KL; Kubicki M J Affect Disord; 2022 Oct; 314():78-85. PubMed ID: 35779673 [TBL] [Abstract][Full Text] [Related]
11. Agmatine as a novel candidate for rapid-onset antidepressant response. Valverde AP; Camargo A; Rodrigues ALS World J Psychiatry; 2021 Nov; 11(11):981-996. PubMed ID: 34888168 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study). Yrondi A; Aouizerate B; El-Hage W; Moliere F; Thalamas C; Delcourt N; Sporer M; Taib S; Schmitt L; Arlicot N; Meligne D; Sommet A; Salabert AS; Guillaume S; Courtet P; Galtier F; Mariano-Goulart D; Champfleur NM; Bars EL; Desmidt T; Lemaire M; Camus V; Santiago-Ribeiro MJ; Cottier JP; Fernandez P; Meyer M; Dousset V; Doumy O; Delhaye D; Capuron L; Leboyer M; Haffen E; Péran P; Payoux P; Arbus C Front Psychiatry; 2018; 9():326. PubMed ID: 30087626 [No Abstract] [Full Text] [Related]
13. Targeting cytokines in reduction of depressive symptoms: A comprehensive review. Shariq AS; Brietzke E; Rosenblat JD; Barendra V; Pan Z; McIntyre RS Prog Neuropsychopharmacol Biol Psychiatry; 2018 Apr; 83():86-91. PubMed ID: 29309829 [TBL] [Abstract][Full Text] [Related]
14. Application of antidepressants in depression: A systematic review and meta-analysis. Yuan Z; Chen Z; Xue M; Zhang J; Leng L J Clin Neurosci; 2020 Oct; 80():169-181. PubMed ID: 33099342 [TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. Kopschina Feltes P; Doorduin J; Klein HC; Juárez-Orozco LE; Dierckx RA; Moriguchi-Jeckel CM; de Vries EF J Psychopharmacol; 2017 Sep; 31(9):1149-1165. PubMed ID: 28653857 [TBL] [Abstract][Full Text] [Related]
16. An altered peripheral IL6 response in major depressive disorder. Money KM; Olah Z; Korade Z; Garbett KA; Shelton RC; Mirnics K Neurobiol Dis; 2016 May; 89():46-54. PubMed ID: 26804030 [TBL] [Abstract][Full Text] [Related]
18. Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2004; 4(7):1-98. PubMed ID: 23074457 [TBL] [Abstract][Full Text] [Related]
19. Inflammatory and Innate Immune Markers of Neuroprogression in Depressed and Teenage Suicide Brain. Pandey GN Mod Trends Pharmacopsychiatry; 2017; 31():79-95. PubMed ID: 28738369 [TBL] [Abstract][Full Text] [Related]
20. T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. Slyepchenko A; Maes M; Köhler CA; Anderson G; Quevedo J; Alves GS; Berk M; Fernandes BS; Carvalho AF Neurosci Biobehav Rev; 2016 May; 64():83-100. PubMed ID: 26898639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]